Videos

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Two phase III studies presented at ASCO 2012 explored the role of lapatinib in the treatment of HER2-positive breast cancer.

The FDA has approved everolimus for treating patients with hormone receptor-positive, HER2 negative breast cancer, when given in combination with the aromatase inhibitor exemestane.

The long-standing debate about postmenopausal hormones and breast cancer gained more evidence to support an increased cancer risk.

Women who have been previously treated for early-stage breast cancer are much less likely to complain of hot flashes if they remain within 10% of their prediagnosis weight.

Breast cancer survival improved significantly in patients who increased consumption of cruciferous vegetables following diagnosis, a study of Chinese women showed.

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial Coprimary Endpoints

Young women who have recently used DMPA for at least 1 year have more than twice the risk of invasive breast cancer as young women who do not report recent use of the injectable contraceptive.

Whether surgically or medically induced, early menopause forces women to deal with a host of emotional, physical, and practical issues.

The FDA has approved pertuzumab combined with trastuzumab and docetaxel for patients who have not received prior treatment for HER2-positive metastatic breast cancer.

Dr. José Baselga, from Massachusetts General Hospital, on combining pertuzumab with trastuzumab

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

CDX-011, a targeted therapy designed to treat patients with advanced breast cancer, appears to increase PFS in TNBC patients who have received multiple prior lines of therapy and express GPNMB.

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

Breast cancer survivors who are younger, closer to the time of surgery, or have upper-extremity lymphedema may be less likely to undergo repeat mammography.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Celldex Therapeutics will present the interim results of a phase IIb study testing the efficacy of a new monoclonal antibody in patients with advanced breast cancer.

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

In a six-week span, José Baselga, MD, PhD, notched a stunning series of milestones in breast cancer research that could potentially change practice in different subtypes of the disease.

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.